US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 7, 2023 (4 years ago)

Aripiprazole Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

What was recalled

Aripiprazole Tablets, USP 5 mg Rx Only, Packaged as a) 30-count bottle, NDC 16729-279-10, UPC 3 16729 27910 9; b) 100-count bottle, NDC 16729-279-01, UPC 3 16729 27901 7; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India

Recalling firm
Accord Healthcare, Inc.
NDC code
16729-279-10
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0366-2023

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Aripiprazole recalls

See all
Class II · Moderate risk Ongoing

Aripiprazole Tablets USP

Reason Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.

Ajanta Pharma USA Inc NDC 27241-056-03 D-0594-2026
Class II · Moderate risk Ongoing

Aripiprazole Tablets

Reason Superpotent drug

Ascend Laboratories, LLC D-0645-2025
Class III · Low risk Ongoing

Abilify

Reason Cross Contamination with Other Products

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk Ongoing

Abilify

Reason Cross Contamination with Other Products

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk Ongoing

Abilify

Reason Cross Contamination with Other Products

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024